Targeting Breathing Limitations to Improve Functional Outcomes in HFpEF
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age55-90
SponsorUniversity of Texas Southwestern Medical Center
About this trial
The overall purpose of this study is to investigate whether pulmonary limitations that increase the oxygen (O2) cost of breathing impact dyspnea on exertion (DOE) and peak exercise capacity in patients with HFpEF and obesity. As per investigator's hypothesis, obesity is likely a significant contributor to DOE and exercise intolerance in patients with HFpEF.
Eligibility criteria
Qualifiers
signs and symptoms of heart failure
an ejection fraction > 0.50;
objective evidence of diastolic dysfunction. elevated biomarkers (NT-proBNP >300 ng/dl) or HF hospitalization
healthy volunteers
Disqualifiers
age < 55 years
BMI > 50 kg/m2
Atrial fibrillation with poorly controlled heart rate
phosphodiesterase type 5 (PDE5) inhibitor use
Trial design
Treatments tested in this trial
- HeO2 gas mixture
- Room air gas mixture
Treatment groups
78 Participants
are divided into 2 treatment groupsLocations
1UT Southwestern Medical Center75390, DallasTexas, United States
Sponsors and collaborators
University of Texas Southwestern Medical Center
Lead sponsor
Source ClinicalTrials.gov